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Abstract
Recently it has been observed that cancer tissue is characterised by an increased variability in DNA methylation patterns.
However, how the correlative patterns in genome-wide DNA methylation change during the carcinogenic progress has not
yet been explored. Here we study genome-wide inter-CpG correlations in DNA methylation, in addition to single site
variability, during cervical carcinogenesis. We demonstrate how the study of changes in DNA methylation covariation
patterns across normal, intra-epithelial neoplasia and invasive cancer allows the identification of CpG sites that indicate the
risk of neoplastic transformation in stages prior to neoplasia. Importantly, we show that the covariation in DNA methylation
at these risk CpG loci is maximal immediately prior to the onset of cancer, supporting the view that high epigenetic diversity
in normal cells increases the risk of cancer. Consistent with this, we observe that invasive cancers exhibit increased
covariation in DNA methylation at the risk CpG sites relative to normal tissue, but lower levels relative to pre-cancerous
lesions. We further show that the identified risk CpG sites undergo preferential DNA methylation changes in relation to
human papilloma virus infection and age. Results are validated in independent data including prospectively collected
samples prior to neoplastic transformation. Our data are consistent with a phase transition model of carcinogenesis, in
which epigenetic diversity is maximal prior to the onset of cancer. The model and algorithm proposed here may allow, in
future, network biomarkers predicting the risk of neoplastic transformation to be identified.
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Introduction
Cancer exhibits widespread DNA methylation (DNAm) changes
compared to normal tissue [1–7]. As demonstrated by a number of
studies, genomic sites undergoing DNA methylation changes in
invasive cancers are already seen to accumulate changes in normal
tissue as a function of age [8–11]. All these observations have been
derived by analysing the changes in mean DNA methylation levels
at specific genomic sites. More recently, studies have begun to
explore and demonstrate the importance of DNA methylation
variability in cancer and other complex diseases [11–15]. As
shown by Hansen et al, cancer tissue is characterised not only by
changes in mean levels of DNA methylation, but importantly also
by increases in DNA methylation variability [12]. This increased
variability is seen at specific genomic regions, both spatially within
the region and the given sample, as well as across samples. This
latter inter-sample variability suggests that the variation may be
due to increased stochasticity [12,13,16]. The importance of
considering DNA methylation variability across samples was
subsequently demonstrated in the context of a prospective study
in cervical cancer: it was shown that cytologically normal samples,
collected three years in advance of neoplastic transformation,
exhibited increased levels of inter-sample DNA methylation
variation compared to age-matched normal samples which did
not progress to neoplasia [13]. Furthermore, by developing a novel
statistical algorithm called EVORA (Epigenetic Variable Outlier
for Risk Prediction Analysis), it was shown that differential DNAm
variability could identify risk markers more robustly than statistical
measures based on differences in mean DNAm levels [17]. This
result was attributed to the risk CpG markers exhibiting outlier
DNAm profiles, in which only a small subgroup of samples exhibit
aberrant DNA methylation. This again supports the view that
DNAm changes arising before the onset of cancer are, in part,
heterogeneous and stochastic [13,17].
From a statistical perspective, all studies so far have only
explored the dynamic changes in the mean and variance of DNA
methylation during carcinogenesis. As yet, no study has fully
explored the changes in DNA methylation correlations that
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accompany the neoplastic process. We refer to the study of
correlations between molecular features and their variance as
‘‘covariation’’.
Here, we decided to explore the dynamic changes in genome-
wide DNA methylation covariation patterns that happen during
the carcinogenic process. We hypothesized that dynamic changes
in the DNAm correlation patterns could shed further light on the
carcinogenic process itself. Specifically, we sought to determine if
the covariation in DNAm progresses in a linear fashion with a
maximum in the invasive cancer stage (as hinted by a previous
study [12]), or if instead, the covariation exhibits a non-linear
dynamics. By using genome-wide DNA methylation data from the
main stages in cervical carcinogenesis, we here demonstrate the
existence of CpG loci whose covariation in DNAm progresses in a
non-linear fashion, exhibiting a maximum in a disease stage prior to
the onset of cancer. This non-linear dynamics is reminiscent of an
underlying phase transition model of disease progression [18],
which we adapt to the epigenetics context and then validate in
independent cohorts, including prospectively collected samples.
Importantly, we demonstrate how the proposed model allows
identification of a network biomarker able to predict the risk of
neoplastic transformation three years in advance of transforma-
tion.
Results
The Dynamical Network Biomarker (DNB) algorithm
We decided to explore the dynamic changes in DNA
methylation covariation patterns during carcinogenesis in the
context of cervical cancer, since for this cancer the cell of origin is
known and is easily accessible in advance of neoplastic transfor-
mation as part of large routine screening programs and clinical
trials (e.g. the ARTISTIC trial) [13,19]. However, even for
cervical cancer, two major obstacles emerge. First, the analysis of
dynamic changes requires extensive time-course data from the
same individual prior to and subsequent to disease diagnosis, yet
such extensive time-course data is not available. Second,
measuring the methylation state of say *14,000 gene promoters
translates into the need to analyze well over 9 million pairwise
correlations, which is a computationally demanding task.
To overcome these challenges, we adapted a physical model of
disease progression, first proposed by Chen et al [18], to the DNA
methylation context (Materials and Methods). Briefly, the
model assumes that disease progresses through a series of physical
phase transitions and that those molecular features (i.e. in our
context these are CpGs) exhibiting a phase transition type
behaviour may be particular important for the progression of that
specific disease. By phase transition behaviour we mean an abrupt
increase and subsequent decrease in the covariation strength of a
set of CpGs which coincides with the transition between two
successive disease stages. Importantly however the model is
otherwise relatively assumption-free, and provides a numerical
prescription, called the Dynamical Network Biomarker (DNB)
algorithm, to identify sets of CpGs, called CpG-modules, which
may exhibit phase-transition like behaviours between progressive
disease stages. A module that does exhibit a non-linear phase-
transition like pattern is called a Dynamical Network Biomarker
(DNB) and here we wanted to assess the possibility that such a
module could be used to indicate the risk of disease progression.
The DNB algorithm circumvents the problem of temporal data
by approximating the unobserved temporal correlations in DNA
methylation between CpGs within a sample by non-temporal
correlations estimated over independent samples, i.e. from
different individuals but crucially all representing the same disease
stage [18] (Materials and Methods). This approximation
assumes that independently collected samples within a disease
stage represent slightly different time points of disease progression
of one representative individual within that same disease stage. To
justify the approximation, we conducted a detailed simulation
study, generating temporal DNA methylation data for a number of
CpGs and individuals and then subsampling one time point for
each individual (Materials and Methods). DNAm profiles of
CpGs making up artificial DNBs were generated according to a
phase transition type model in which the variation and co-
variation in DNAm increases and becomes maximal just before
the transition point (e.g. the onset of neoplasia) is reached
(Materials and Methods). We note that such a model is
consistent with the view that epigenetic plasticity may be highest in
stages prior to the onset of neoplastic transformation (Fig. 1). As
observed across a number of different individuals this means that
epigenetic profiles may be least predictable (i.e appear most
stochastic) in the stage just prior to neoplasia and cancer. Applying
the DNB algorithm to the simulated data revealed sensitivity
values around 0.5, indicating that the non-temporal approxima-
tion may be able to capture DNBs in real data (Fig. S1 in Text
S1). Thus, based on this simulated data, it is therefore possible to
apply the DNB algorithm on real data using a coarse-grained time
variable with as many time points as there are disease stages.
The DNB algorithm also circumvents the problem posed by the
high-dimensional correlation space (w9million correlations), since
it uses a semi-supervised clustering approach to perform dimen-
sional reduction, whereby the salient dynamical changes are
captured by a relatively small number of ‘‘gene-modules’’ (in our
context ‘‘CpG-modules’’) (Materials and Methods). Thus, for
each data set representing a given disease stage, the DNB
algorithm infers a number of CpG-modules (Materials and
Methods). For each of these inferred CpG-modules and in each
disease stage, one then computes a ‘‘relevance score’’ which
measures the amount of DNAm variation and the strength of
DNAm covariation of the CpG-module members. Specifically, the
score for a given module m in disease stage t is estimated by the
formula
Author Summary
DNA methylation is a covalent modification of DNA which
can regulate how active genes are. DNA methylation is
altered at many genomic loci in cancer cells, leading to
widespread functional disruption. Importantly, DNA meth-
ylation alterations across the genome are seen even in
early carcinogenesis. Although the pattern of DNA
methylation change during carcinogenesis has been
studied at individual genomic loci, no study has yet
analysed how these patterns change at a systems-level,
specifically how do DNA methylation patterns at pairs of
genomic sites change during disease progression. Doing
so can shed light on how the epigenetic diversity of cell
populations changes during the carcinogenic process. This
study performs a systems-level analysis of the dynamic
changes in DNA methylation correlation pattern during
cervical carcinogenesis, demonstrating that epigenetic
diversity is maximal just prior to the onset of cancer.
Importantly, this supports the view that the risk of cancer
development is closely related to an increase in epigenetic
diversity in apparently healthy cells. In addition, the study
provides a computational algorithm which successfully
identifies the altered genomic sites confering the risk of
cervical cancer.
Dynamics of Epigenetic Diversity in Carcinogenesis
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where SDmt is the average standard deviation of the DNA
methylation profiles of the CpGs making up the module as
assessed over samples within disease stage t, PCCmt denotes their
average pairwise Pearson correlation coefficient, and PCC
(o)
mt
denotes the average Pearson correlation between the module
features and their complement, i.e. all other non-module CpGs
(Materials and Methods). As shown by Chen et al, this
heuristic score can be motivated solely on theoretical principles
[18] (see also Materials and Methods). However, as we argue
next, it can also be motivated biologically (Fig. 1). Specifically, we
seek groups of CpGs with large co-variability in specific disease
stages, which means high variability and absolute pairwise
correlations. Thus, the relevance score should be proportional to
SDmt, since this represents the average variability in DNAm of
these CpGs in a given disease stage t. Similarly, the score should
be proportional to the ratio PCCmt=PCC
(o)
mt , since this measures
the coherence of the module CpG’s DNAm correlations relative to
the rest of the assayed CpGs (Fig. 1A–B). Thus, for a given fixed
module m, studying how the score Smt changes as a function of
disease stage t will inform us about the dynamic changes in DNAm
covariation patterns that the module CpGs/genes incur during
carcinogenesis. By construction, this score is likely to be maximal
for the disease stage in which the module was inferred. However,
for the same module, the score it obtains in other disease stages
will provide highly non-trivial information about the underlying
dynamics and biological relevance of its member CpGs/genes
Figure 1. The dynamics of DNA methylation in carcinogenesis. A) Progressive changes in DNA methylation are shown for a number of cells
and for three disease stages, as shown. For each cell we only depict 6 CpG sites, which are assumed to map to high-CpG dense promoters and thus
most start out as unmethylated (yellow colour). With time, some of these CpGs acquire methylation (blue) and once aquired these are relatively
stable marks. However, at the cellular population level, the hypothesis is that DNA methylation patterns become least predictable, i.e become most
stochastic and diverse, in stages just prior to the onset of neoplasia. Measured in time, covariances in DNA methylation will be maximal in this high
risk stage because no dominant subclone exists. Consistent with observations, CpG sites become more homogeneously methylated (more
predictable) once the cancer has developed. B) Upper panel: Hypothesized pattern of variation of the average DNA methylation as measured over a
population of cells in each disease stage. Depicted are the patterns for 6 hypothetical CpGs. Observe how the variability in DNA methylation for
certain CpGs would be maximal in the high-risk stage, due to temporal variations in the dominating subclone population. Lower panel: Relevance
network representation of the correlation strengths with disease stage with thick edges representing strong correlations. CpGs exhibiting maximal
variation (SD) and covariation (PCC), but low correlation to other CpGs (PCCo), at the transition point to neoplasia define a Dynamic Network
Biomarker (DNB).
doi:10.1371/journal.pcbi.1003709.g001
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during carcinogenesis. We can further use independent data from
similar or other disease stages to validate the score predictions of
the modules derived from the training data.
The dynamics of DNA methylation covariation patterns in
cervical carcinogenesis
In order to test the DNB algorithm in the DNA methylation
context, we collected DNA methylation data from six progressive
stages in cervical carcinogenesis, all generated using the same
Illumina Infinium 27k platform [20], which measures DNA
methylation at over 27,000 CpG sites (*14,000 gene promoters).
Because infection by the human papilloma virus (HPV) is a
necessary, but not sufficient, factor for cervical cancer [19],
normal samples were stratified according to HPV status (if
known). Thus, the six disease stages were HPV2 normal cells,
HPV+ normal cells, HPV2 normal cells which become a cervical
intraepithelial neoplasia of grade 2 or higher (CIN2+) three years
later (‘‘CIN2+ precursor cells’’), HPV+ CIN2+ precursor cells,
CIN2+ cells and invasive cervical cancer (Fig. 2A). The DNA
methylation data was drawn from a total of four different studies,
abbreviated as ART, LBC1, LBC2 and CC (Fig. 2A). The ART
data set consists of 152 samples, encompassing the first four
disease stages. To clarify, these 152 samples are all cytologically
normal, yet 75 of these became CIN2+ after 3 years and are thus
denoted ‘‘precursor CIN2+’’. Data sets LBC1 and LBC2 are
similar in that they both contain CIN2+ samples, yet only LBC1
contains normal HPV2 samples, whilst the normal samples in
LBC2 were HPV+ (Fig. 2A). Finally, data set CC contains
invasive cervical cancers in addition to normal cervical samples
(presumed HPV2).
To infer modules of CpGs and to investigate their broad
dynamic changes in DNAm covariation, we first focused on
samples from only the 3 main stages: HPV2 normal cells, CIN2+
cells, and invasive cancer. These samples were drawn from data
sets LBC1 and CC, which constitute our training data (Figs. 2A–
B). Application of the DNB algorithm to these two data sets
resulted in four distinct CpG modules called LBC1-A, LBC1-B,
CC-A and CC-B, the terminology reflecting the data set which
they were derived from (Fig. S2 in Text S1). To clarify, we note
that inference of CpG modules via the DNB algorithm requires
samples which represent a normal reference (Materials and
Methods). Thus, in deriving LBC1-A and LBC1-B we used as
reference the normal samples of data set LBC1, whereas for CC-A
and CC-B we used the normal samples of data set CC. This
strategy ensures that results are not confounded by study-specific
effects.
Estimation of the relevance (i.e. covariation strength) scores of
these four modules in each of the 3 main disease stages revealed
highly distinctive dynamical behaviour, with LBC1-B and CC-A
modules exhibiting sharp increases specific to their disease stage
(Fig. 3). Curiously, module LBC1-B, in contrast to LBC1-A,
exhibited a clear maximum in the CIN2+ disease stage, i.e prior
to invasive cancer. To demonstrate that this is not an artefact of
the module construction and score estimation procedure, we
evaluated the relevance score of this same module in an
independent data set encompassing CIN2+ samples (LBC2 set,
Fig. 2). The score value attained by the LBC1-B module in this
independent set was highly concordant with that in the training
data, a result which was also true for the other inferred modules
(Fig. 3). Thus, the sharp maximum exhibited by the LBC1-B
module in the CIN2+ disease stage is a biological feature of the
CpG sites making up the module and not the result of
overfitting.
Non-linear dynamics of DNAm covariation patterns
signals the transition to neoplasia
The non-linear dynamics with the sharp maximum exhibited by
the LBC1-B module is reminiscent of an underlying phase
transition model, and thus we posited that these specific CpGs
could be specially important for cervical carcinogenesis. Indeed,
we posited that the relevance score of these sites may already show
increases in disease stages that precede CIN2+ and could thus be
used for risk prediction. To test this, we computed the relevance
score of the LBC1-B module CpGs in independent samples
representing HPV+ normal cells, as well as HPV2 and HPV+
precsursor CIN2+ cells. These precursor samples represent
cytologically normal samples at measurement, but which 3 years
later became CIN2+ and were drawn from the ART data set
(Fig. 2, [13]). Remarkably, the relevance score of the LBC1-B
module estimated in these independent samples representing these
intermediate disease stages were also intermediate, lying in
between those of normal HPV2 cells and CIN2+ samples
(Fig. 4). In fact, the relevance score of the LBC1-B module
exhibited a gradual monotonic increase from normal HPV2 cells
to normal HPV+ cells, to precursor HPV2 and HPV+ CIN2+
cells and finally to the CIN2+ stage (Fig. 4). In order to further
test the robustness of the data, we also recomputed the relevance
score of this module for invasive cervical cancers stratified
according to their stages, and these were never higher than for
the CIN2+ disease stage (Fig. 4). We also computed the relevance
scores of the other 3 modules in these independent samples, and
interestingly, none of the other 3 modules exhibited a maximum
prior to the onset of invasive cancer (Fig. S3 in Text S1). Thus,
this highlights the distinctive nature of the LBC1-B module.
To test if the LBC1-B module can predict the risk of neoplastic
transformation, we first asked if the CpGs making up the LBC1-B
module overlapped with the 140 risk-associated CpGs previously
derived using the EVORA algorithm [13]. We observed that the
LBC1-B module, consisting of 91 CpG markers, exhibited a strong
overlap (33/91, Pv10{16, Fig. 5A–B) with the 140 risk CpGs
reported in [13]. This is remarkable given that the LBC1-B
module and the 140 risk CpGs were derived from independent
data sets and different disease stages (LBC1 and ART, respec-
tively). Not surprisingly, the LBC1-B markers were highly enriched
for PolyComb Group Target genes (PCGTs) [21] (Fisher test,
Benjamini Hochberg adjusted Pv10{10), in line with the
observed strong PCGT enrichment of the 140 risk CpG sites
[13]. Importantly none of the other modules exhibited an overlap
with the 140 risk CpG sites as strong as our candidate DNB
(Fig. 5A).
To formally demonstrate that the inferred LBC1-B module can
predict the risk of neoplasia we computed an average methylation
risk score over the 91 CpG markers for each sample in the ART
set (see Fig. 2A, [13]). This risk score was predictive of prospective
CIN2+ status with an AUC=0.62 (P~0:005, Fig. 5C), similar to
the AUC of the 140 risk CpGs reported in [13] and higher than
that of the other inferred modules (Fig. 5C). Thus, LBC1-B is a
candidate dynamical network biomarker (DNB), signaling the
transition to a neoplastic state.
Increased covariance of risk CpG sites prior to CIN2+ is
followed by homogenization in invasive cancers
That the relevance score of the LBC1-B/DNB module reaches
a maximum in the CIN2+ stage, with a subsequent decline
observed in invasive cancer indicates that for these particular CpG
sites there is a reduction in the DNAm covariances as evaluated
across the cancers. To understand why DNAm covariances in
Dynamics of Epigenetic Diversity in Carcinogenesis
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cancer may be reduced, we generated heatmaps of DNA
methylation for the 91 DNB CpGs across all major disease stages
ranking samples within each disease stage according to the fraction
of methylated sites (using a relaxed bw0:2 threshold) (Fig. 6).
This fractional methylation score exhibited a striking bi-modality
within the CIN2+ disease stage, with some CIN2+ samples
exhibiting high methylation fractions and others exhibiting much
lower levels (Fig. 6). Remarkably, almost all 91 CpGs acquired
extensive methylation in the great majority of invasive cancers.
Thus, this clearly demonstrates that CpG sites already undergoing
changes before morphological transformation, continue to under-
go further DNAm modification in CIN2+ and cancer cells. The
observation that samples are particularly diverse and bi-modal in
the CIN2+ stage suggests that epigenetic diversity may be highest
in this disease stage, with those CIN2+ samples exhibiting the
methylator phenotype (i.e. a high methylation fraction) being on
course to becoming invasive cancers.
Risk CpGs are specially associated with HPV status and
age
Many of the risk CpGs making up the DNB module exhibit
significant methylation increases in CIN2+ cells, since they were
selected by comparing DNAm levels between CIN2+ and normal
cells. Based on the observed gradual increase in the relevance
score of the DNB from normal HPV2 to normal HPV+, to
precursor CIN2+ HPV2 and subsequently to precursor CIN2+
Figure 2. Datasets and analysis strategy used. A) Distribution of samples according to dataset (LBC1, CC, ART, LBC2) and disease stage in
cervical carcinogenesis. Datasets LBC1 and CC were used for training, i.e. the DNB algorithm was applied to these sets only to infer candidate DNB
modules. Datasets ART and LBC2 were used to test the predictions of the module scores obtained in the training data. B) The overall analysis strategy
was to use LBC1 and CC as training sets, to infer candidate DNB modules across the 3 main stages of cervical carcinogenesis: normal, CIN2+ (cervical
intraepithelial neoplasia of grade 2 or higher) and invasive cervical cancer, as shown. After computation of the relevance scores, measuring the
strength of covariation in DNAm, of the inferred modules, we identified a candidate DNB(s) as the one exhibiting a maximum in the score in a stage
(CIN2+) prior to invasive cancer. Finally, for this DNB module, we compute its score in independent data sets profiling samples from a previously
considered disease stage (i.e. LBC2 for CIN2+) or from other intermediate disease stages (e.g. ART for normal HPV2, normal HPV+, precursor CIN2+
HPV2 and precursor CIN2+ HPV+ cells). Prediction is that the scores in the CIN2+ LBC2 samples should agree with those of the CIN2+ LBC1 samples,
and that the score values in disease stages N(HPV+), pre-CIN2+(HPV2) and pre-CIN2+(HPV+) should be intermediate between N(HPV2) and CIN2+.
doi:10.1371/journal.pcbi.1003709.g002
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HPV+ cells, we argued that the CpGs making up the DNB module
would also be associated with HPV status. Averaging the methyl-
ation values over the 91 DNB CpGs for each sample in the ART
dataset (Fig. 2A) confirmed a significant increase in the HPV+
precursor CIN2+ cells compared to their HPV2 counterparts
(Fig. S4 in Text S1). To further confirm this association with HPV
status, we investigated the DNA methylation profiles of these 91
CpGs in head & neck cancer [22], another cancer for which HPV is
a risk factor: we observed that these CpGs were overwhelmingly
hypermethylated in HPV+ head & neck cancers compared to their
Figure 3. Broad dynamic changes of inferred CpG-modules. The changes in the relevance score as a function of main disease stage (as
indicated) for each of the inferred modules. LBC1-A and LBC1-B were derived from comparing CIN2+ to normals (HPV2 normals) in set LBC1, while
modules CC-A and CC-B were derived by comparing cervical cancers (CC) to HPV2 normal cervical tissue in data set CC. The stages shown are
N(HPV2), CIN2+, and cervical cancer (CC). In red, we show the relevance score attained by these same modules in an independent test data set
consisting of CIN2+ samples (LBC2 set).
doi:10.1371/journal.pcbi.1003709.g003
Figure 4. Dynamical Network Biomarker (DNB) in cervical carcinogenesis. The changes in the relevance score of the LBC1-B CpG module,
termed a DNB, as a function of disease stage: the stages shown are N(HPV2), N(HPV+), preCIN2(HPV2), preCIN2(HPV+), CIN2+, CC stages 1,2 and 3.
Note that the samples from stages N(HPV+), preCIN2(HPV2) and preCIN2(HPV+) were drawn from completely independent test sets and that these
samples exhibit relevance scores which are intermediate between N(HPV2) and CIN2+, in line with their disease stage. Darkred dashed line indicates
hypothetical switching point in the transition from cytologically normal cells at risk of CIN2+ to CIN2+. (Abbrev: N=Normal, preCIN2+: precursor
CIN2+ cells, CIN2+= cervical intraepithelial neoplasia of grade 2 or higher, CC= cervical cancer).
doi:10.1371/journal.pcbi.1003709.g004
Dynamics of Epigenetic Diversity in Carcinogenesis
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HPV2 counterparts (Fig. S5 in Text S1). We also asked if the
average methylation over the 91 CpGs would correlate with age,
another risk factor for CIN2+. Interestingly, this was indeed the case
and it did so independently of HPV status and prospective CIN2+
status (Fig. S4 in Text S1). To further assess the biological
significance of these 91 CpGs, we randomly selected another 91
Figure 5. DNB module predicts risk of neoplastic transformation. A) Fractional overlaps of the four inferred modules with the 140 risk CpG
set identified using EVORA [13] in the ART cohort. B) Statistically significant overlap of the 91 DNB module CpGs with the 140 risk CpGs. Note that by
construction, none of the CpG markers in module LBC1-A overlap with those in the DNB (LBC1-B). C) ROC AUC analysis for the average methylation
risk score for the DNB (LBC1-B) module. We provide the AUC and associated P-values of significance for LBC1-B (in red), and for the other 3 modules
(in black).
doi:10.1371/journal.pcbi.1003709.g005
Figure 6. DNA methylation changes of DNB markers during cervical carcinogenesis. Heatmap depicts the DNAm levels of the 91 CpGs
making up the DNB module (LBC1-B) across six stagtes in cervical carcinogenesis, as indicated. In each disease stage, samples have been ordered
according to the average fraction of the 91 CpGs that exhibit a methylation beta-value larger than 0.2 (see upper panel).
doi:10.1371/journal.pcbi.1003709.g006
Dynamics of Epigenetic Diversity in Carcinogenesis
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CpGs from the same dataset, and recomputed the association
between average methylation and HPV status or age. In only 2 of
10,000 random selections of 91 CpGs, did we observe discriminatory
P-values as extreme as the ones for the actual 91 LBC1-BCpGs (Fig.
S4 in Text S1, FDRv0:001 for both age and HPV status). Thus,
this shows that these particular CpG sites undergo preferential
methylation increases in normal tissue as a function of age and in
pre-neoplastic lesions as a function of current HPV status.
Discussion
To the best of our knowledge, this is the first study to analyse
patterns of DNAm covariation during carcinogenesis. We used
cervical cancer as our model since for this cancer it is possible to
acquire relatively large numbers of samples prior to neoplastic
transformation, thus allowing the stages prior to neoplasia and
cancer to be assessed. From a computational perspective,
analysing pairwise correlations in DNAm of ,27,000 CpGs is
technically very demanding, due to the need to analyse millions of
pairwise correlations. To circumvent this problem, we used a
statistical algorithm, grounded on physical principles [18,23], to
allow us to identify CpG modules exhibiting interesting dynamical
changes in DNAm covariation patterns.
By applying this algorithm to only three disease stages of
cervical carcinogenesis (normal, CIN2+, cancer), we identified one
CpG module, called a dynamical network biomarker (DNB),
whose covariation exhibited a non-linear pattern with maximal
covariation during the CIN2+ disease stage, i.e. a stage prior to
invasive cancer. By using DNAm data from independent CIN2+
samples and other disease stages we further validated this result,
thus demonstrating the biological and statistical significance of the
non-linear dynamics exhibited by this specific CpG module. The
non-linear dynamics of the module’s covariation strength is
reminiscent of a phase transition model, suggesting that the CpGs
making up this module may be of particular biological
significance. Confirming this, the DNB module exhibited a very
strong overlap with 140 risk CpG sites which we identified
previously using independent samples prior to neoplastic trans-
formation [13]. We stress again that this overlap was highly
statistically significant and non-trivial given that the two sets of
CpGs were derived from entirely different data sets. This strong
overlap meant that the DNB could predict the prospective risk of
CIN2+ in cytologically normal cells 3 years in advance of
morphological transformation with a statistically significant AUC
value of 0.62 (P~0:005). Confirming the role of the DNB CpGs as
risk indicators of prospective CIN2+ status, we found that they
were strongly associated with HPV status in cells of normal
cytology. Moreover, the same CpGs were also associated with
HPV status in head & neck cancer. Importantly, the other
modules which the algorithm inferred did not exhibit maximal
covariation prior to cancer, and these modules were on the whole
also less interesting, exhibiting significantly lower overlaps with the
previously identified 140 risk CpG sites.
In order to understand the biological significance of these
findings, we generated heatmaps of the DNAm patterns of the
DNB CpGs across all disease stages. This showed that these
particular CpG sites exhibited a striking bi-modality, specifically
within the CIN2+ stage, with some CIN2+ samples exhibiting
hypermethylation at most of these sites, whilst other CIN2+
samples showed hypermethylation at only far fewer CpGs. This bi-
modality is therefore a major driver of the increase in DNAm
covariation at these CpG sites. In the invasive cancer stage, all of
these CpG sites become hypermethylated in effectively all cancers,
thus lowering the covariation. Biologically, this suggests that the
emergence of an invasive cancer requires most of these CpG sites
to become methylated. The observed bi-modality in the CIN2+
stage further suggests that some CIN2+ samples are much closer to
the invasive cancer stage than others. This indicates that CIN2+ is
a stage where epigenetic diversity across samples is maximal or
near-maximal, meaning that a sample’s epigenetic profile is least
predictable (i.e. most stochastic). It is entirely plausible that this
maximum in inter-sample epigenetic diversity reflects a disease
stage where epigenetic mosaicism is also highest within individual
tissue samples, consistent with the hypothesis put forward by
Feinberg and colleagues that epigenetic diversity is a driver of the
carcinogenic process [2]. Indeed, since the DNAm measurements
considered here were taken in samples that consist of whole cell
populations, a likely interpretation of the observed phase transition
dynamics is a concomitant increase in epigenetic plasticity within
individual samples, i.e. an increase in the number of distinct
epigenetic subclones [11,24]. This increase in epigenetic mosai-
cism then leads to a substantial increase in the risk of a cancer cell
emerging. The subsequent decrease in variability and co-
variability observed in invasive and highly proliferative cervical
cancer (Fig. 4) may reflect either the emergence of a dominant
tumour subclone or evolutionary convergence of tumour sub-
clones. Thus, the heterogeneity or diversity in DNA methylation
patterns undergoes an abrupt increase at the onset of neoplasia
with more homogeneous profiles before and after this epigenetic
switching point. Importantly, the variability and heterogeneity in
DNAm profiles remains higher in cancer compared to normal cells
(Fig. 4), consistent with previous observations [12].
The non-linear phase transition dynamics behaviour of the
DNB module could have deep practical implications. In fact, given
that the DNB was identified from only 3 stages in carcinogenesis
(normal cells, CIN2+ and invasive cancer), this raises the exciting
possibility that risk biomarkers could be identified from multi-stage
non-prospective data, although validation will require prospective
samples, as done here.
It is also important to discuss the potential merits of the phase
transition DNB framework for risk prediction, in comparison to
the EVORA (Epigenetic Variable Outliers for Risk prediction
Analysis) algorithm [13], specially since both are able to predict
prospective CIN2+ status with similar AUC values. First of all,
EVORA is a univariate feature selection method that aims to
identify methylation outliers, in contrast to the DNB framework
which performs feature selection in a multivariate fashion relying
heavily on the dynamic changes in DNA methylation covariation
patterns. Hence, the DNB formalism does not rely on the existence
of methylation outliers. This is an important point, because as
shown by us previously, methylation outliers may not be as
prominent in other more heterogeneous tissue types such as blood
[17], whence why EVORA may not be applicable to prospective
studies conducted in blood tissue or in surrogate tissues unrelated
to the cell of origin of the cancer. Thus, the DNB framework may
provide a more general mathematical framework for identifying
risk biomarkers from epigenetic profiles in a wider range of tissues.
Secondly, if DNA methylation changes are highly variable and
dynamic in cell populations predisposed to neoplasia, then
methylation levels per se may be less useful as risk biomarkers.
Consistent with this, differential methylation statistics were less
sensitive to identify risk markers in the prospective setting [13,17].
Instead, the strong correlations between highly dynamic markers
would provide a more stable, network-based, risk biomarker [18].
Thirdly, we have seen that the DNB formalism can identify disease
risk biomarkers from non-prospective multi-stage data. Indeed, the
DNB module was identified by comparing normal to CIN2+ cells
and by further observing the dramatic increase in the DNB score
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between normal and CIN2+ cells and the subsequent drop in
invasive cancer. In contrast, EVORA appears to be less useful to
identify risk biomarkers from disease stages where cells have
already undergone neoplastic transformation [17].
Finally, it is also important to discuss the observations made
here in the context of the original dynamic system-omic model of
Chen et al [18]. Even though the DNB algorithm can be
motivated purely on biological grounds, without the need to
invoke large dynamic changes in DNAm, the original algorithm
was derived from an underlying dynamic model which assumes
that DNA methylation levels may be highly variable on time-
scales relevant to disease progression. Although at the single cell
level, DNA methylation is a relatively stable and mitotically
heritable mark, in rapidly proliferating cells DNAm replication
errors can occur [25]. Most importantly, at the population level
of thousands of cells, recent work has shown that DNA
methylation can indeed be highly variable in time [26]. In fact,
DNAm polymorphisms and stochastic variation has been
observed in time course in-vitro studies of relatively large normal
cell populations [26]. It is therefore plausible that in cells which
are predisposed to neoplastic transformation, that DNA methyl-
ation changes are less stable, particularly, when measured across
a population of cells, since specific subclones may outcompete
others for a period of time, with other subclones characterised by
a different DNAm profile taking over at a later stage. Supporting
the view that DNAm levels can be dynamic in carcinogenic cells,
we recently observed such dynamic changes in a time course
Illumina 450k DNAm profiling experiment covering 480,000
CpG sites in glioma and normal neural stem cells, both treated at
baseline with a BMP (bone morphogenetic protein) differentiation
inducing factor (BMP4), and followed up for a maximum of 64
days, with measurements taken at baseline, 8, 16, 32, 48 and 64
days. Specifically, we identified a non-negligible fraction of
CpGs that acquired significant hypermethylation (Dbw0:2)
during the time course, but which subsequently lost methylation
(Dbv{0:2) at a later time point, independently of passage
number, and with more pronounced changes observed in one
glioma stem cell line (Fig. S6 in Text S1). Thus, these data show
that a proportion of DNA methylation changes in a cell
population are not retained and are thus variable in time.
Hence, it is equally plausible that some of the DNAm changes
occuring in preneoplastic and neoplastic tissues could have a
dynamic component which could indicate a particular pheno-
typic state of the underlying tissue.
In summary, our results are consistent with a model in which
the variability and co-variability in DNA methylation increases
significantly as cells approach a ‘‘switching point’’ between normal
cytology and neoplasia. We propose that the ‘‘system-omics’’ DNB
framework presented here should be explored further as a means
of identifying disease risk biomarkers from multi-stage DNA
methylation data, or from fully prospective studies profiling
samples from easily accessible tissues such as blood or buccal cells
collected years in advance of diagnosis. In these studies the time of
sampling to disease diagnosis is variable between individuals.
Hence, with sufficient numbers of individuals, the framework
presented here could be exploited to identify epigenetically
changing modules which could provide more robust markers of
disease risk.
Materials and Methods
Data
The main DNA methylation data sets used in this work were all
generated with Illumina Infinium 27k beadchips, have all been
published previously [13,17] and are publicly available from GEO
(www.ncbi.nlm.nih.gov/geo/). See references for GEO accession
numbers. The distribution of samples in each data set according
to disease stage is provided in Figure 2.
Brief review of the Dynamical Network Biomarker (DNB)
algorithm
The original DNB algorithm is grounded on a dynamic
‘‘system-omic’’ model as described in detail in [18]. Although
there the application was to gene expression data, here we adapt
the formalism to the epigenetics context, and specifically to DNA
methylation data. Thus, we assume that we have DNA methyl-
ation profiles across tens of thousands of CpGs and for a number
of samples representing different progressive disease stages.
Although the original theoretical model describes dynamic
changes in time, happening in one individual, we shall consider
a surrogate approach (see next subsection for justification) in which
time is replaced by disease stage. Specifically, we assume that there
are a number of progressive disease stages, labeled by R, and we
assume that there are nR independent samples in disease stage R.
Furthermore, we assume that the transitions between specific
disease stages, which we here call ‘‘switching points’’, can be
modelled as fold-bifurcations [18]. A theorem in dynamical
systems theory, as applied to omic data, then states that a module
of CpGs exists satisfying the following properties as the switching
point is approached [18]:
N The variance in methylation of the module CpGs increases.
N The correlation in methylation between the module CpGs
increases.
N The correlation between module CpGs and other measured
CpGs decreases.
We stress that these are theoretical predictions which follow
from a minimal set of fairly realistic assumptions [18]. Thus, for a
given set/moduleM of CpGs in a disease stage R, it was proposed
that a score, SMR be computed as
SMR~SDMR
PCCMR
PCCo,MR
ð2Þ
where SDMR is the average standard deviation of the DNA
methylation profiles of the CpGs making up the moduleM across
the nR samples in disease stage R, PCCMR denotes their average
pairwise Pearson correlation coefficient as estimated across the nR
samples, and PCCo,MR denotes the average Pearson correlation
between the modules CpGs and their complement, i.e. all other
CpGs not in the module M. Thus, the score SMR becomes
maximal as the switching point is approached and would drop in
value beyond this point.
It is important to note that, of course, not all CpG modules one
may define or construct would exhibit an increase in this score as a
switching point is approached. However, those modules which do
show dramatic increases in the score between two successive
disease stages are of particular interest, since the associated CpGs
could then be used as disease risk indicators. These modules are
called Dynamical Network Biomarkers, and hence refered to as
‘‘DNB modules’’ [18].
Dynamic DNA methylation simulation model
Since acquiring dynamical genomic data from single patients is
at present impractical, we propose to explore correlations in
molecular profiles cross-sectionally, i.e. by taking single time point
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measurements (‘‘snapshots’’) of a sufficient number of different
patients, all with the same stage of disease. To demonstrate that
this cross-sectional approach is feasible and that computation of
correlations over snapshot samples can capture dynamical network
biomarkers (DNBs), we devised a simulation model. Without loss
of generality, we let the simulation represent a scaled-down version
of real data. Thus, we shall assume that we can measure the level
of some molecular entity (here DNA methylation of a CpG site) at
500 sites (‘‘CpGs’’) in a genome, and for each of 25 patients. We
shall further assume unobserved time-course molecular profiles for
each of these patients (with &100 equidistant time points). Each
patient is assumed to be in the same pre-disease stage, so that as
time goes on, each patient approaches the critical transition point,
characterised by the onset of disease. According to the theoretical
framework in [18], a DNB marker exists for each of the patients
and we assume that this DNB could in principle be detected by
measuring the molecular profiles. The DNB itself consists of a set
of highly correlated (or anticorrelated) CpGs each of which
exhibits an increase in methylation variance as time approaches
the critical point. At earlier time points the correlation of the DNB
genes is either absent or is masked by other sources of variation.
The precise DNB is allowed to vary from patient to patient, but we
also allow for some overlap. This is biologically justified since we
know that particular genes are more likely to be targets for
differential methylation or differential expression in early stage
disease. For instance, the importance in cancer of PolyComb Group
Target genes (PCGTs), which account roughly for over 1500 genes in
the human genome is undisputed [4,5] and further evidence for their
role in preneoplastic disease was presented in [13]. Thus, we assume
that the specific DNBs in each patient are drawn from a common
pool of 50 ‘‘risk-PCGTs’’, i.e 10% of the 500 features, which is
roughly the proportion of PCGT genes to all genes in the human
genome. However, we want the patient-specific DNBs to vary from
patient to patient, so the CpG (or gene) set for each patient-specific
DNB is constructed by randomly sampling 20 of the 50 CpGs. Thus,
the expected overlap of any two patient-specific DNBs is small and on
the order of 8 CpGs. This again is similar to the inter-sample overlap
of risk-CpGs observed in [13]. For each of the 25 patients we thus
construct a hypothetical time course of molecular profiles over 500
CpGs and 100 time points. For the 20 DNB CpGs selected from the
pool of 50 risk PCGT CpGs, we take their methylation values to vary
in time according to
bgs(t)~m(t)zvm(m(t))zvN (t) ð3Þ
where bgs(t) denotes the methylation b -value at CpG site
g[DNBs in individual s at time t (t[½0,1), averaged over a large
number of cells making up the sample. In other words, the simulation
model is formulated not at the single cell level, but at the cellular
population level. We further note that the methylation b -value at
CpG g in sample s represents the fraction of cells that have that
particular CpG site methylated. Thus, this value is bounded
between 0 and 1, as one would expect for a random variable from
a beta distribution. Formulating the simulation model on this
scale has the advantage that the values are readily interpretable as
methylation fractions. In the above model, m(t) describes the
increase in the mean methylation level with time and we assume
this takes the form
m(t)~
1
2
ea(t{1) ð4Þ
with a parameter a, which we choose to be a~2:5. The exact
value of this parameter is not important, but we are implicitly
assuming (without loss of generality) that the CpG sites start out
unmethylated with b -values around 0.05. The maximum
attainable mean value is 0.5 corresponding to t~1. This
assumption too is not necessary but is convenient as explained
below. We point out that the non-linear increase in mean
methylation is also not essential and we could replace the above
exponential with a linear function of time. The second term in
equation 3 describes the increased variability in methylation as a
function of the mean methylation, whereas the third term
represents an intrinsic biological and technical noise which we
shall assume to be stationary so that vN (t)~vN .
Since, as explained above, methylation data is beta-
distributed we must reformulate the above in the logit-
transformed basis
ygs(t)~log
bgs(t)
1{bgs(t)
ð5Þ
in order to correctly incorporate the noise term which is
Gaussian in the logit basis, i.e.
ygs(t)~y(t)zsy(y(t))zsN (t) ð6Þ
where sN (t) denotes random normal deviates. Specifically, we
assume that [27]
sy(y(t))*N (0, 1Dy(t)Dgzc )
sN (t)*N (0,sN )
where N (0,s) denotes a normal deviate of mean zero and
standard deviation s, and g and c are parameters that we take to
have values 1 and 0.8, respectively. These values are chosen to
generate realistic profiles. To justify the above model for the
variance, we first note that the DNA methylation measurements
are taken over large collections of cells. Thus, when the mean
methylation is 0.5, half of the cells have the particular CpG site
methylated (assuming a binary methylation state), while the
other half have this site unmethylated. Thus, at this point the
expected variability in methylation across the cell population is
maximal. With the above model, the variance in methylation is
indeed maximal at t~1 since m(1)~0:5 and y(1)~0. The above
model also ensures that the rate of variance increase grows as
the transition point is reached in line with previous models [27].
The constant value sN is chosen to be equal to (Dy(0)Dgzc){1, as
required, since it should equal the intrinsic stochastic variation
at the initial time point.
For the 450 non-PCGT CpG sites we assume an uncorrelated
stationary pattern, i.e.
ygs(t)~sN V g =[DNBs ð7Þ
and so these features remain stably unmethylated.
Finally, to generate the methylation profiles on the appropriate
scale, we transform the ygs(t) values back into b -values using the
inverse of equation 5. We note again that since variability in DNA
methylation patterns is maximal at t~1, we consider t~1 the
transition or switching point representing the onset of a new
disease stage, e.g. neoplasia.
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Having generated hypothetical time course molecular profiles
bgs(t), we next sample for each individual s a random time point
t[½0,1, thus defining a 500625 ‘‘static snapshot’’ matrix mgs. This
data matrix represents what in practice would be the observed
data.
Identification of the DNB in the simulated data
Given this observed data matrix, the question is now
whether clustering over the genes can identify a module of
CpGs which captures a ‘‘consensus’’ DNB across all the
considered patients. This consensus DNB should consist of the
selected 50 risk ‘‘PCGT’’ CpG sites. To test this we first
compute from mgs, the corresponding correlation matrix
between the CpGs. Next, from this correlation matrix we
construct an unweighted adjacency matrix with edges repre-
senting significant pairwise correlations, and finally use the
spectral decomposition algorithm [28] to identify modules (i.e.
communities of relative large edge density) in the resulting
graph. Next, we select the module with the largest variance in
methylation (here we average the standard deviation in
methylation of the constituent module CpGs) across samples
and declared this to be the candidate DNB. Sensitivity and
positive predictive values (PPV) are then calculated and
significance P-values of overlap between the true 50 DNB
markers (i.e the 50 risk PCGT CpGs) and those found in the
candidate DNB are estimated using a binomial test. A total of
100 different Monte Carlo runs (in each run new time-course
DNA methylation profiles and a new observed data matrix is
generated) were performed to test for robustness.
Construction of candidate DNB modules in cervical
carcinogenesis
Candidate DNB modules were inferred by adapting a previous
procedure [18]. Briefly, we compared DNA methylation profiles
between the normal and CIN2+ samples of set LBC1 and the
normal and cervical cancer samples of set CC (see Fig. 2).
Specifically, we used a Bayesian shrinkage linear model (limma)
[29] to derive in each case a ranked list of top discriminative
CpGs. The list of CpGs was selected using a false discovery rate
cutoff of 0.05 and imposing a threshold on the standard deviation
in DNAm as measured across the CIN2+ or cancer samples,
respectively. The thresholds on the standard deviations were
chosen from density plots of the standard deviation across all
CpGs, which revealed clear boundaries where the density
dropped significantly. The resulting thresholds were in the range
0.05–0.1. However, in cases where too many CpGs passed this
threshold, we capped the number of CpGs at a maximum of
around 1000. To identify clusters/modules we then applied the
robust partitioning around medoids algorithm [30] with a
Pearson distance correlation metric and with the number of
clusters variable between 2 and 10. The optimal number of
clusters was estimated using the average silhouette width [30] and
was found to be two in both the LBC1 and CC data sets, resulting
in 4 modules in total, denoted as (LBC1-A, LBC1-B, CC-A,
CC-B).
Module score computation and identification of the DNB
in cervical carcinogenesis
For each of the four inferred modules, a module score was first
estimated in the two training data sets, i.e. LBC1 and CC (see
Fig. 2), according to the equation 2 above [18]. Briefly, the
estimation of the score also requires a normal reference. For each
disease stage we used as normal reference the phenotypically
normal specimens of the corresponding study profiling the
samples. For the CIN2+ (all HPV+) samples from LBC1 we used
the normal samples of that same study as reference. For the
cervical cancer samples we used as reference the 15 normal
tissue samples from the same study. Thus, for each CpG in a
module we first estimated the mean and standard deviation in
DNAm across the normal reference samples. The DNAm
profiles across the samples in the disease stage where then
renormalised relative to this reference, resulting in normalised
z-scores reflecting deviations from the normal reference. The
standard deviation of these z-scores across the samples in the
disease stage were then computed for each CpG in the module.
The average of these standard deviations defines the measure
SD in equation 2. The average of the absolute pairwise
Pearson correlations between the CpG DNAm profiles in the
module defines the measure PCC. To estimate the correlations
of the module CpGs to other CpGs not in the module, we
randomly selected CpGs in the complement, computing the
absolute correlations of the module CpGs with these and then
averaging. A global average was obtained by running this
randomisation procedure a total of 10 times, which resulted in
stable values. Finally, the score for a candidate DNB module
was computed as in equation 2.
To identify DNBs we then studied the profile of the scores for
each of the 4 modules (LBC1-A, LBC1-B, CC-A, CC-B) across the
3 main stages represented in the LBC1 and CC datasets, i.e.
normal cells, CIN2+ and invasive cervical cancer. A DNB is a
module exhibiting a characteristic dramatic increase in the score
(at CIN2+ stage) with a subsequent drop at a later stage (i.e.
invasive cancer).
Testing of the modules scores in independent data
In order to test reproducibility, the module scores of the four
modules were also estimated in an independent data set (LBC2)
consisting of normal cells and CIN2+ samples. Thus, this allowed the
reproducibility of the score values obtaining in the CIN2+ disease
stage of dataset LBC1 to be assessed in a completely independent set
(LBC2). In addition, module scores were also evaluated in another
independent dataset (ART), profiling normal HPV2, normal HPV+
and precursor CIN2+ cells (both HPV2 and HPV+). Because the
latter three stages are intermediate between normal HPV2 and
CIN2+, we can further validate the framework since the prediction is
that the values for the intermediate stages should also be
intermediate between those for the normal HPV2 and CIN2+
stages. We note that as normal reference in the score computation
we used the normal samples of LBC2 for the CIN2+ stage of LBC2,
and the normal HPV2 samples of ART for the other 3 stages of the
ART set. We remark that in the ART set we had many more
samples, allowing the normal HPV2 state to be considered separate
from the normal HPV+ state. However, results are unchanged if they
had been merged.
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